Ourotech

Ourotech helps pharma companies reduce false positive cancer therapies early using hydrogels to create predictive, high drug-resistance, in-vitro tumor models

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Waterloo, ON, Canada
  • Currency USD
  • Founded January 2015
  • Employees 5
  • Incorporation Type Other
  • Website ourotech.ca

Company Summary

Ourotech helps pharma companies determine the best drug candidates in their lead/preclinical pipeline to reduce false positives early. Ourotech creates proprietary reagents that can be used for engineering predictive, high drug resistance tumor models. Ourotech's first product, Genesis, can be used to mimic the mechanical properties and pH and oxygen gradients of solid in-vivo tumors to supplement the flaws of mice models.

Team

  • Duleek Ranatunga

  • Ali Nikdel
    CTO

    10 years of startup experience in biopharma (1st employee of biopharma startup from development to launch)
    PhD Candidate (Jan 2017) in Chemical Engineering
    Thesis on combining biological and mathematical/software models (big data) for predictive drug screening
    10 years of cell culture experience
    Experience in animal testing facilities

  • Zhi Yuan William Lin
    Biomaterials R&D

    14 publications in biomaterials and tissue engineering
    Academic research: Harvard-MIT, Univeristy of Waterloo
    Industry research: Fluidigm
    Previous startup experience

  • Christina (Yuyao) Wang
    Head of Manufacturing

    3 years of chemical product manufacturing experience
    Supply chain management experience
    Master's in Chemical Engineering
    Minor in Entrepreneurship

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free